OMNIAB, INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
OMNIAB, INC. (OABI) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $6.11 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-06
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $6.11M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $9.16M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $3.23M.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $6.46M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $6.11M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $9.16M 10-Q · filed 2026-05-07 |
| 2025-09-30 | $3.23M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $6.46M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $9.68M 10-Q · filed 2025-05-08 |
| 2024-09-30 | $3.39M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $6.79M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $10.23M 10-Q · filed 2024-05-09 |
| 2023-09-30 | $3.41M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $6.80M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $10.14M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |